Azenta (NASDAQ:AZTA) Issues Quarterly Earnings Results

Key Points

• Azenta missed expectations: reported EPS of ($0.04) versus $0.10 expected and revenue of $144.8M (vs. $148.3M est.), with revenue up 1.4% year‑over‑year and a negative net margin of 10.34%.
• Stock moved on the news: shares rose to $24.61 on heavy volume, the company has a $1.13B market cap and a 52‑week range of $19.87–$41.73.
• Mixed analyst sentiment and high institutional ownership: the consensus rating is "Hold" with a $41.33 target after several downgrades/price cuts, and institutions own about 99% of the stock.

Azenta (NASDAQ:AZTA - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.14), FiscalAI reports. The company had revenue of $144.80 million for the quarter, compared to analyst estimates of $148.26 million. Azenta had a positive return on equity of 1.43% and a negative net margin of 10.34%.Azenta's revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.01 earnings per share.

Azenta Price Performance

NASDAQ:AZTA traded up $0.28 on Tuesday, hitting $24.61. 1,847,559 shares of the company's stock were exchanged, compared to its average volume of 809,043. The firm has a 50-day moving average price of $23.56 and a 200-day moving average price of $30.23. Azenta has a 52 week low of $19.87 and a 52 week high of $41.73. The company has a market cap of $1.13 billion, a P/E ratio of -18.23 and a beta of 1.43.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Wall Street Zen cut Azenta from a "buy" rating to a "hold" rating in a research note on Saturday, February 7th. Evercore dropped their price target on Azenta from $50.00 to $45.00 and set an "outperform" rating on the stock in a research report on Thursday, February 5th. TD Cowen restated a "hold" rating on shares of Azenta in a report on Wednesday, February 4th. Needham & Company LLC restated a "buy" rating and set a $44.00 price objective on shares of Azenta in a report on Tuesday, March 17th. Finally, Weiss Ratings lowered Azenta from a "sell (d-)" rating to a "sell (e+)" rating in a report on Monday. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Azenta has an average rating of "Hold" and a consensus target price of $41.33.

Institutional Trading of Azenta

Several institutional investors and hedge funds have recently bought and sold shares of AZTA. Caitong International Asset Management Co. Ltd raised its stake in shares of Azenta by 2,067.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 802 shares of the company's stock worth $27,000 after purchasing an additional 765 shares in the last quarter. Osaic Holdings Inc. grew its position in shares of Azenta by 44.9% in the 2nd quarter. Osaic Holdings Inc. now owns 1,242 shares of the company's stock valued at $39,000 after acquiring an additional 385 shares during the period. Van ECK Associates Corp increased its stake in shares of Azenta by 141.2% during the 4th quarter. Van ECK Associates Corp now owns 1,585 shares of the company's stock worth $53,000 after purchasing an additional 928 shares during the last quarter. Quantbot Technologies LP acquired a new position in shares of Azenta during the 3rd quarter worth about $57,000. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Azenta by 472.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,002 shares of the company's stock valued at $92,000 after purchasing an additional 2,478 shares during the period. Institutional investors own 99.08% of the company's stock.

About Azenta

Azenta, Inc NASDAQ: AZTA is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta's Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.